MedTrace Logo

Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors

NCT00684957 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-07-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if giving growth hormone or insulin-like growth factor-1 (IGF-1) to subjects with growth hormone deficiency effects cardiovascular risk factors differently.

Conditions

  • Growth Hormone Deficiency

Interventions

DRUG

Recombinant Human Growth Hormone

300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)

DRUG

Recombinant Human IGF-1

30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)

Sponsors & Collaborators

Principal Investigators

  • Pamela U. Freda, M.D. · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2012-10-31
Completion
2012-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00684957 on ClinicalTrials.gov